Trends in the use of adjuvant therapy for resected intrahepatic cholangiocarcinoma: getting ahead of the data  

作　　者：Jordan M.Cloyd Timothy M.Pawlik 

机构地区：[1]Department of Surgery,Division of Surgical Oncology,The Ohio State University Wexner Medical Center,Columbus,OH,USA

出　　处：《Hepatobiliary Surgery and Nutrition》2021年第4期515-517,共3页肝胆外科与营养（英文）

摘　　要：Intrahepatic cholangiocarcinoma(ICC),the second most common primary liver malignancy,is an aggressive cancer occurring with increasing global incidence.Significant advances in our understanding of its pathogenesis and molecular underpinnings,diagnostic and staging capabilities,and locoregional and systemic treatment options have occurred over the past several decades(1).

关 键 词：HEPATIC ADJUVANT PATHOGENESIS 

分 类 号：R73[医药卫生—肿瘤]